NCT06350487View on ClinicalTrials.gov

The Efficacy of Enavogliflozin in Heart Failure With Preserved Ejection Fraction

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Heart Failure, Preserved Ejection Fraction
Interventions
DRUG

SGLT2 inhibitor

Enavogliflozin (0.3mg oral tablet once daily) will be administrated.

Trial Locations (1)

06351

Samsung Medical Center, Seoul

All Listed Sponsors
lead

Samsung Medical Center

OTHER

NCT06350487 - The Efficacy of Enavogliflozin in Heart Failure With Preserved Ejection Fraction | Biotech Hunter | Biotech Hunter